Dr. Reddy’s Expands Strategic Collaboration with Amgen in India
September 16 2016 - 6:54AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY) today announced that it has expanded its strategic
collaboration with Amgen, one of the world's leading independent
biotechnology companies, to market and distribute three of Amgen’s
medicines in India in the therapy areas of oncology and
osteoporosis. Under the terms of the collaboration, Dr. Reddy’s
will commercialise XGEVA® (denosumab),
Vectibix® (panitumumab) and
Prolia® (denosumab) in India.
In 2015, Dr. Reddy’s announced an initial strategic
collaboration with Amgen to execute a full range of regulatory and
commercial services to seek approval of and launch Amgen’s
Kyprolis® (carfilzomib), BLINCYTO® (blinatumomab) and Repatha™
(evolocumab) in India. The collaboration leverages the capabilities
of both companies, combining Amgen's innovative therapies with Dr.
Reddy’s deep understanding of patient and physician needs in
India.
M.V. Ramana, Executive Vice President and Head of Emerging
markets and India Business, Dr. Reddy’s Laboratories Limited, said,
“We are delighted to continue our relationship with Amgen as it
strengthens our constant endeavor to enhance patients’ access to
novel treatment options across therapy areas. These medicines
provide unique treatment options to physicians to address unmet
medical need in the area of oncology and osteoporosis.”
Penny Wan, Amgen Vice President and General Manager, Japan Asia
Pacific Region, said, ”We are happy to strengthen our relationship
with Dr. Reddy’s. Amgen is committed to addressing unmet medical
needs of patients in India, and we are pleased with the commitment
Dr. Reddy’s has demonstrated toward making our medicines available
in India as quickly as possible.”
XGEVA is a RANK ligand (RANKL) inhibitor and is approved in
India for the prevention of skeletal related events in patients
with advanced malignancies involving bone.
Vectibix is an epidermal growth factor receptor (EGFR)
antagonist approved in India for the treatment of adult patients
with wild-type KRAS metastatic colorectal cancer (m-CRC) as first
line treatment as monotherapy following disease progression, in
wild type RAS m-CRC as first-line combination with FOLFOX and in
second line in combination with FOLFIRI after prior treatment with
fluoropyrimidine-based chemotherapy (excluding irinotecan).
Prolia is a RANK ligand (RANKL) inhibitor approved in India for
treatment of post-menopausal women with osteoporosis at high risk
for fracture and also for treatment of increased bone mass in men
with osteoporosis. Often referred to as the "silent epidemic,"
osteoporosis is a global problem that is increasing in significance
as the population of the world both increases and ages. The World
Health Organization (WHO) has recently identified osteoporosis as a
priority health issue along with other major non-communicable
diseases.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses – Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may,"
"will," "should," "expects," "plans," "intends," "anticipates,"
"believes," "estimates," "predicts," "potential," or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults, currency exchange rates, interest rates, persistency
levels and frequency/severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160916005336/en/
Dr. Reddy’s Laboratories Ltd.INVESTOR
RELATIONSSaunak SavlaPh:
+91-40-49002135saunaks@drreddys.comorMEDIA RELATIONSCalvin
PrinterPh: +91-40-49002121calvinprinter@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024